...
首页> 外文期刊>RSC Advances >Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications
【24h】

Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications

机译:用于MRI应用的氧化锰纳米粒子的放松和毒理学性质

获取原文

摘要

Manganese oxide nanoparticles (MONs) have received growing attention as alternative T _(1) MRI contrast agents due to the association of commercial gadolinium-based contrast agents with nephrogenic systemic fibrosis. Since the seminal publication first describing the use of MONs as positive T _(1) contrast agents, there is an ongoing impetus to develop MONs of higher T _(1) signal intensity for better diagnostic efficacy. Indeed, various MON-based nanoprobe designs have been proposed, such as the employment of a mesoporous nanomaterial with MONs evenly dispersed within, or the traditional coating of a biocompatible layer onto the surface of MONs to form a core–shell configuration. Recent advances in this field also propose stimuli-responsive MONs that capitalize on an acidic dissolution or in situ reduction to release Mn ~(2+) ions for a multi-fold increase in MRI contrast. However, the potential nanotoxicity of MONs remains a key obstacle to the clinical translation of MON-based T _(1) contrast agents. Due to the wide variety of functionalities and physicochemical properties of MONs, there is also a lack of consensus on the toxicological properties of MONs. In addition, the r _(1) relaxivity of MRI contrast agents typically decreases at higher field strength. Hence, it highlights the need to develop MON-based contrast agents with higher relaxivities. In this regard, this article aims to present a thorough review of MONs for MRI applications, with particular emphasis on their relaxivity and toxicological properties. In order to systematically review the current state-of-the-art for the development of MONs for MRI applications, the MON-based T _(1) contrast agents are categorized based on the structure of the nanomaterial system. Key parameters that influence the nanotoxicity of MONs are also examined while the absorption, distribution, metabolism and excretion of MON in vivo are evaluated to discern how long the nanoparticles will be present within the body, as well as to predict the organs or tissues in which they distribute.
机译:氧化锰纳米颗粒(MONS)由于商业钆的造影剂与肾肾上腺素纤维化的关联而产生替代的T _(1)MRI造影剂。由于首先描述使用Mons作为阳性T _(1)造影剂的原创出版物,因此存在持续的动力来开发更高的T _(1)信号强度的蒙似的,以便更好的诊断疗效。实际上,已经提出了各种基于一半的纳米孔设计,例如使用介孔纳米材料的使用常见地分散在内部或将生物相容性层的传统涂层均匀地分散到Mons的表面上以形成核心壳构造。该领域的最新进展还提出了刺激响应的蒙特,以利用酸性溶解或原位还原,以释放Mn〜(2+)离子以进行MRI对比度的多倍。然而,Mons的潜在纳米毒性仍然是Mon-T _(1)造影剂的临床翻译的关键障碍。由于蒙版的各种功能和物理化学特性,缺乏对MONS毒理学特性的共识。另外,MRI造影剂的R _(1)的放松率通常在更高的场强下降低。因此,它突出了开发基于周一的造影剂的需要具有更高的放松性。在这方面,本文旨在彻底审查Mons为MRI申请,特别强调其放松和毒理学性质。为了系统地回顾目前的用于MRI应用的MONS的最新技术,基于MON的T _(1)造影剂基于纳米材料系统的结构进行分类。影响MONOS纳米毒性的关键参数,同时评估MON中MON的吸收,分布,代谢和排泄,以辨别纳米颗粒在体内的时间,以及预测器官或组织他们分发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号